Antonella Bacchieri
Sigma-Tau
17 Papers
122 Citations
Antonella Bacchieri is an academic researcher from Sigma-Tau. The author has contributed to research in topics: Population & Dihydroartemisinin/piperaquine. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin
Jan A. Staessen,Jan A. Staessen,Lutgarde Thijs,Katarzyna Stolarz-Skrzypek,Antonella Bacchieri,John Barton,Ezio degli Espositi,Peter W. de Leeuw,Mirosław Dłużniewski,Nicola Glorioso,Andrzej Januszewicz,Paolo Manunta,Viktor Milyagin,Yuri Nikitin,Miroslav Souček,Chiara Lanzani,Lorena Citterio,Mario Timio,Andrzej Tykarski,Patrizia Ferrari,Giovanni Valentini,Kalina Kawecka-Jaszcz,Giuseppe Bianchi +22 more
TL;DR: In 5 concurrently running double-blind cross-over studies rostafuroxin did not reduce blood pressure at any dose, and minor side-effects occurred with similarly low frequency on roStafuroXin and placebo.
Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin.
Stephanie E. Reuter,Allan M. Evans,Sepehr Shakib,Yvonne Lungershausen,Barbara Francis,Giovanni Valentini,Antonella Bacchieri,David Ubben,Silvia Pace +8 more
TL;DR: Food was found to significantly impact on the pharmacokinetics of piperaquine and dihydroartemisinin, and co-administration of food with these anti-malarials by populations consuming a typical Western diet should be avoided to reduce the risk of toxic side effects.
26
Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India
Nicola Gargano,David Ubben,Silva Tommasini,Antonella Bacchieri,Marco Corsi,P C Bhattacharyya,Bappanad H. K. Rao,Nagesh Dubashi,Vas Dev,Susanta K. Ghosh,Ashwani Kumar,Bina Srivastava,Neena Valecha +12 more
TL;DR: DP is a new ACT displaying high efficacy and safety in the treatment of uncomplicated P. falciparum malaria and could potentially be considered for the first-line treatment of undiscovered malaria in India.
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
John E.A. Blair,Cezar Macarie,Witold Rużyłło,Antonella Bacchieri,Giovanni Valentini,Maria Bianchetti,Peter S. Pang,Matthew E. Harinstein,Hani N. Sabbah,Gerasimos Filippatos,Mihai Gheorghiade +10 more
TL;DR: The novel inotropic and lusitropic agent, istaroxime, was tested in acute heart failure syndromes using a comprehensive assessment of cardiovascular function in addition to hemodynamic measurements.
22
OASIS-HT: design of a pharmacogenomic dose-finding study.
Jan A. Staessen,Tatiana Kuznetsova,Rok Acceto,Antonella Bacchieri,Eva Brand,Michel Burnier,Hilde Celis,Lorena Citterio,Peter W. de Leeuw,Jan Filipovský,Albert Fournier,Kalina Kawecka-Jaszcz,Paolo Manunta,Yuri Nikitin,Eoin O'Brien,Josep Redon,Lutgarde Thijs,Patrizia Ferrari,Giovanni Valentini,Giuseppe Bianchi +19 more
TL;DR: The OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points, and to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone.
20